Navigation Links
Anthera Pharmaceuticals to Present at Annual Piper Jaffray Healthcare Conference
Date:11/27/2013

HAYWARD, Calif., Nov. 27, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, announced today that Paul F. Truex, President and Chief Executive Officer, and May Liu, Senior Vice President of Finance and Administration, will present a corporate update at the 2013 Annual Piper Jaffray Healthcare Conference.

Anthera will present at 4:00PM ET, December 3rd, at the Palace Hotel in New York City.

About Blisibimod

Anthera is developing blisibimod, a selective inhibitor of B-cell activating factor (BAFF), to explore its clinical utility in various autoimmune diseases including systemic lupus erythematosus (SLE) and IgA nephropathy. Blisibimod is a novel fusion protein, or peptibody, and is distinct from an antibody. Anthera owns worldwide rights to blisibimod in all potential indications. BAFF, also known as BLyS (B lymphocyte stimulator), is a tumor necrosis family member and is critical to the development, maintenance and survival of B-cells. B-cells represent a critical component of human immune response to infection and other pathogens. However, abnormal elevations of B-cells and BAFF may lead to an overactive immune response which may damage normal healthy tissues and organ systems. Multiple clinical studies with BAFF antagonists have reported the potential benefit of BAFF inhibitors in treating patients with lupus and rheumatoid arthritis.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases. Anthera's Phase 3 development product candidate, blisibimod, targets elevated levels of B-
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Anthera Pharmaceuticals Reports 2013 Third Quarter Financial Results, Clinical and Regulatory Update
2. Anthera Pharmaceuticals Announces Emerging Data from Phase 2 Open-Label Extension Study to be Presented at the ACR/ARHP 2013 Annual Scientific Meeting
3. Anthera Pharmaceuticals Reports 2013 Second Quarter Financial Results
4. Anthera Announces Initiation of BRIGHT-SC Phase 2 Clinical Study in IgA Nephropathy with Blisibimod
5. Anthera Pharmaceuticals Announces Receipt of Nasdaq Notice
6. Anthera Pharmaceuticals Announces Personnel Changes
7. Anthera Pharmaceuticals to Present at Annual Jefferies Healthcare Conference
8. Anthera Pharmaceuticals Reports 2013 First Quarter Financial Results
9. Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study
10. Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secures $18.5 Million Committed Equity Financing Facility
11. Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014  Decision Resources Group,s experts are ... the Affordable Care Act (ACA), which has ... therapies. The ACA altered how Managed Care ... and expanded access via government-supported programs. Dynamic ... marketplaces set up by states or the ...
(Date:7/31/2014)... July 31, 2014 Touro University California,s College ... selected as the recipient of a $150,000 grant by ... the University to increase research and classroom space on ... technology for the study of health sciences, and will ... needs and interests of our students," said Shelley ...
(Date:7/31/2014)... Iowa , July 31, 2014 For ... California , Art,s-Way Scientific has earned ... With competition in over 30 categories, MBI,s ... for MBI members, which include building manufacturers, dealers, and ... is an excellent example the capability of our team," ...
Breaking Medicine Technology:Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4Touro University California Garners Grant From Long Foundation 2Art's Way Scientific Earns Prestigious Modular Building Institute Award 2Art's Way Scientific Earns Prestigious Modular Building Institute Award 3Art's Way Scientific Earns Prestigious Modular Building Institute Award 4
... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... serving the pharmaceutical, biotechnology, and medical device industries, ... today announced its financial results for third-quarter 2010. ... (Logo: http://photos.prnewswire.com/prnh/20040705/CNM002LOGO ) Third-Quarter ...
... LLC (US HIFU), a world leader in minimally invasive ... the Sonablate ® 500 (Sonablate) and Sonatherm ® ... 18 clinical trial sites involved in the recurrent prostate ... prostate cancer trial, or STAR trial, is a multi-center ...
Cached Medicine Technology:WuXi PharmaTech Announces Third-Quarter 2010 Results 2WuXi PharmaTech Announces Third-Quarter 2010 Results 3WuXi PharmaTech Announces Third-Quarter 2010 Results 4WuXi PharmaTech Announces Third-Quarter 2010 Results 5WuXi PharmaTech Announces Third-Quarter 2010 Results 6WuXi PharmaTech Announces Third-Quarter 2010 Results 7WuXi PharmaTech Announces Third-Quarter 2010 Results 8WuXi PharmaTech Announces Third-Quarter 2010 Results 9WuXi PharmaTech Announces Third-Quarter 2010 Results 10WuXi PharmaTech Announces Third-Quarter 2010 Results 11WuXi PharmaTech Announces Third-Quarter 2010 Results 12WuXi PharmaTech Announces Third-Quarter 2010 Results 13WuXi PharmaTech Announces Third-Quarter 2010 Results 14WuXi PharmaTech Announces Third-Quarter 2010 Results 15WuXi PharmaTech Announces Third-Quarter 2010 Results 16US HIFU Announces That 18 Recurrent Prostate Cancer Clinical Trial Sites Are Open For Enrollment 2US HIFU Announces That 18 Recurrent Prostate Cancer Clinical Trial Sites Are Open For Enrollment 3
(Date:7/31/2014)... 2014 In today’s world, a good night’s ... Snoring and sleep apnea (a medical problem where the airway ... bed partners of the rest they need to face their ... snores and 20 million people in the United States alone ... and treated; and of those treated, many cannot tolerate their ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 The vineyards are ... the upcoming harvest. And, to celebrate, folks are gearing up ... Sunday, September 6 and 7, 2014 along the Leelanau ... an optional walk or run through the vineyards start-ing at ... Suttons Bay. A unique course between rows of grapevines offers ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 United Theological ... its faculty, Anthony Le Donne and Peter J. Bellini. ... Also new to United is a Director of Non-Degree ... 1. , Anthony Le Donne, Assistant Professor of ... Kingdom. He teaches New Testament, Second Temple Judaism, and ...
(Date:7/31/2014)... 31, 2014 Ticket Down is ... Finals tickets at the Sun Life Stadium in Miami ... Cup is now underway. Residents and diehard soccer fans from ... watch the Guinness International Champions Cup final in person at ... in the tournament have been split into two groups where ...
(Date:7/31/2014)... 2014 Daily Gossip indicates in its ... for this health problem. However, this is not a ... was created by Peter Bansby, who decided to reveal ... all over the world find a unique way of ... to view pros and cons from a full Neuropathy ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Leelanau Peninsula’s Annual Harvest Stompede Offers a Unique Vineyard Course for Walkers, Runners and Wine Tasters 2Health News:Growing Seminary Welcomes New Faculty 2Health News:Guinness International Champions Cup Finals Tickets in Miami, FL Available at Ticket Down 2Health News:Guinness International Champions Cup Finals Tickets in Miami, FL Available at Ticket Down 3Health News:Neuropathy Miracle Review Reveals Peter Bansby's Unique Cure Method 2
... ... of their new ReActive™ Court Surface. , ... Salt Lake City, Utah (PRWEB) February 7, 2010 -- SnapSports today announced the ... new system is its adherence to metric standards, while still utilizing all of the patented ...
... support, researchers say , FRIDAY, Feb. 5 (HealthDay News) -- ... a new study suggests. , Researchers conducted PET scans of ... social status and social support. The results suggest that social ... dopamine D2/D3 receptors in an area of the brain called ...
... Amy ... her nursing career more than 30 years ago. Amy will assume the CEO post on March ... Washington, DC (Vocus) February ... Washington, D.C., where she began her nursing career more than 30 years ago. Amy will assume ...
... ... their newest “Select Partner”. As a MedicalSpaMD Select Partner, Shine Teeth Whitening gives ... $300M teeth whitening industry with no training and no equipment required. , ... Salt Lake City, UT (Vocus) ...
... ... Creams N, Lotions Facebook page or followers of their Twitter handle, @100sheabutter. Five randomly selected ... , ... 2010 -- Reforma Group is announcing a special Valentine,s Day giveaway to fans of their ...
... , , LAKE FOREST, Ill. ... Mutual Holding Company and Health Fitness Corporation (NYSE AMEX: ... has granted early termination of the waiting period under the ... of HealthFitness. , (Logo:   http://www.newscom.com/cgi-bin/prnh/20090122/CG61641LOGO ) , On ...
Cached Medicine News:Health News:SnapSports Releases ReActive Court Surfacing For The International Sports Market 2Health News:Dopamine Levels in Brain May Determine Social Status 2Health News:Providence Hospital Selects Amy Freeman as President and CEO 2Health News:Providence Hospital Selects Amy Freeman as President and CEO 3Health News:MedicalSpaMD Announces Exciting New Partnership 2Health News:Romantic Valentine's Day Gift Ideas: Keep Your Skin Soft & Naughty Gift Basket Giveaway 2Health News:Trustmark and HealthFitness Announce Early Termination of Hart-Scott-Rodino Waiting Period 2Health News:Trustmark and HealthFitness Announce Early Termination of Hart-Scott-Rodino Waiting Period 3Health News:Trustmark and HealthFitness Announce Early Termination of Hart-Scott-Rodino Waiting Period 4
... Bottled Water, The Simplicity personal water system ... currently use bottled water. In addition to ... store bottled water, your laboratory applications may ... be absorbed from containers and cause water ...
... to 12 L/min of Type I ultrapure ... The Super-Q Plus System is designed to ... has been pretreated by reverse osmosis, distillation ... ultrapure water quality which exceeds Type I ...
... System Produces Type I Water Directly from Tap, ... for scientists who need 5 to 15 L ... have easy access to acceptable quality pretreated water. ... L/min of ultrapure (Type I) water on demand, ...
TOPLOAD 3200/0.01G, BL3200H. Touch-key external calibration only. Requires calibration weights (either 2000g or 3000g). 120/240V A/C adapter, Lock-down Ring, In-use Protective Cover....
Medicine Products: